CUSP06 put on FDA fast track for platinum-resistant ovarian cancer
The U.S. Food and Drug Administration (FDA) has granted fast-track status to CUSP06, Oncusp Therapeutics’ treatment candidate for platinum-resistant ovarian cancer. This designation…
News
Tuspetinib as part of triple-combo therapy showing potential in AML
A triple-combination therapy using tuspetinib, Aptose Biosciences‘ experimental oral therapy, is showing potential in treating adults with newly diagnosed acute myeloid leukemia (AML),…
PAC-MANN blood test shows high accuracy in ID’ing pancreatic cancer
A new blood test called PAC-MANN can detect the most common type of pancreatic cancer with high accuracy, according to a study led by…
KROS 101 can activate T-cells to target brain cancer in lab studies
An experimental immune-modulating therapy called KROS 101 was able to activate immune cells to kill glioma cells in laboratory experiments, according to new preclinical…
FDA gives RMAT status to Vigil immunotherapy for ovarian cancer
The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to Gradalis’ experimental immunotherapy platform Vigil (Gemogenovatucel-T) as…
Complete response to CAR T-cell therapy reported in RRMM patient
A first patient with relapsed/refractory multiple myeloma (RRMM) treated with CT0590, Carsgen Therapeutics’ CAR T-cell therapy, showed a complete response to the…
Cancer vaccine galinpepimut-S may improve AML survival: Analysis
Treatment with the cancer vaccine galinpepimut-S (GPS) is showing promise to potentially improve survival in people with acute myeloid leukemia (AML), a type of…
Checkpoint inhibitors may be effective Pan-NEN immunotherapy
Certain immunotherapies may be effective in some cases of pancreatic neuroendocrine neoplasms (Pan-NEN), a rare type of pancreatic cancer, according to a study that…
Glioblastoma Research Program funded to study brain cancer
The Lundin Cancer Fund has donated $4 million to the Canadian Cancer Society to create the Glioblastoma Research Program, a five-year initiative to…
Azenosertib may be effective at treating cyclin E1+ PROC: Study
About a third of women with cyclin E1+ platinum-resistant ovarian cancer (PROC) responded to treatment with azenosertib, an experimental therapy by Zentalis. That’s according…
